Latest Zidovudine Stories

HIV-infected young adults, blacks, injection drug users and the uninsured less likely to have disease under control while taking antiretroviral drugs Tens of thousands of Americans taking potent antiretroviral therapies, or ART, to keep their HIV disease in check may not have as much control over the viral infection as previous estimates have suggested, according to results of a study by AIDS experts at Johns Hopkins and the University of Pennsylvania. In what is believed to be the...

Safety, tolerability study to enroll MSM in the United States and Puerto Rico Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection. The trial involves a strategy known as...

(Ivanhoe Newswire) – A new medical essay argues switching patients on one type of antiretroviral therapy (ART) to another, to see whether the new drug is as good as the preventing replication of the HIV virus, may be unethical and may not benefit patients. The studies, termed non-inferiority trials, are only ethical if participants can meaningfully benefit from the treatment change and are more likely to benefit than suffer harm, according to Andrew Carr from the HIV unit in St Vincent's...

A new collection of compounds, called "bryologs" – derived from a tiny marine organism – activate hidden reservoirs of the virus that currently make the disease nearly impossible to eradicate. Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure. Patients must adhere to a demandingly regular drug regimen that carries plenty of side effects. And while the therapy may be...

A increasingly used type of HIV study which involves switching patients on one type of antiretroviral therapy (ART) to another, to see whether the new drug is as good as the at preventing replication of the HIV virus, may be unethical, according to a new Essay published in this week's PLoS Medicine. The studies, termed non-inferiority trials, are only ethical if participants can meaningfully benefit from the treatment change and are more likely to benefit than suffer harm, according to Andrew...

Connie K. Ho for redOrbit.com – Your Universe Online The U.S. Food and Drug Administration (FDA) recently approved Truvada, which decreases the risk of HIV invention in uninfected individuals who have a high risk of contracting HIV Infection or who are engaged in sexual activities with a partner who is HIV-infected. Truvada is the first drug approved by the FDA that focuses on reducing the risk of HIV infection acquired through sexual activities. Taken daily, the drug is be used for...

AVAC Lays out Priorities to Ensure Access NEW YORK, July 11, 2012 /PRNewswire-USNewswire/ -- Publication of data from three trials of pre-exposure prophylaxis (PrEP) for HIV - including the pivotal Partners PrEP trial - today in the New England Journal of Medicine provides strong evidence that HIV-negative men and women who consistently take a daily antiretroviral (ARV) pill (either TDF/FTC, brand name Truvada, or TDF, brand name Viread) can significantly reduce their risk of HIV...

PLEASANTON, Calif., July 2, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new HIV viral load test has been approved by the United States Food and Drug Administration (FDA) and will be commercially available in the US later this year. Like other innovative Roche HIV tests, this one targets two highly conserved regions of the HIV-1 genome and avoids any regions which are current drug targets, thus providing increased reliability as compared to other...

redOrbit Staff & Wire Reports - Your Universe Online The fight against AIDS could get some help this summer, as the Food and Drug Administration (FDA) is expected to approve a drug used to prevent the transmission of HIV, the AIDS virus. Made by Gilead Sciences of Foster City, California, Truvada is already widely used in combination with other drugs to treat patients with HIV. To help the approval process, 2 studies have been published in The Lancet which show just how effective...

(Ivanhoe Newswire) -- About 0.2% of pregnant women are HIV positive and 1/3 will pass the virus to their baby before it is born if no treatment is given. A new study breaches the safety and efficacy of adding antiretroviral drugs (HIV treatment drugs) to standard zidovudine prophylaxis (standard HIV prevention drugs) in infants of mothers with HIV who did not receive antenatal antiretroviral therapy because of late identification. Within 48 hours after their birth, researchers randomly...